Key result
Elevated baseline serum sST2 (OR 11.663) and BNP (OR 11.862) levels independently predicted ineffective treatment response in heart failure patients, with a combined model achieving an AUC of 0.929.
Why the study?
To evaluate the association between baseline serum sST2 and BNP levels and treatment outcomes in HF patients, and to assess their predictive value.
Do baseline serum sST2 and BNP levels predict treatment efficacy in patients with heart failure?
Case-Control (n=162)
No
Do baseline serum sST2 and BNP levels predict treatment efficacy in patients with heart failure?
Odds Ratio: 11.663 (95% CI 3.239–41.997)
p-value: p=<0.001
Baseline serum sST2 and BNP levels are independent predictors of treatment response in heart failure patients, and their combined use provides excellent predictive accuracy.
May support sST2 and BNP for HF prognosis; leaves open whether they guide therapy before prospective validation.
OBJECTIVES: To evaluate the association between baseline serum soluble stimulator gene 2 (sST2) level, B-type natriuretic peptide (BNP) level and treatment outcomes in Heart failure (HF) patients, and to assess their predictive value. METHODS: A retrospective case-control study was conducted on 162 HF patients treated at Longgang People's Hospital from August 2021 to July 2023. Patients were categorized into effective (n=138) and ineffective (n=24) groups based on New York Heart Association (NYHA) functional classification post-treatment. Serum sST2 and BNP levels were measured using enzyme-linked immunosorbent assay, and cardiac function parameters, including left ventricular ejection fraction (LVEF) were assessed via echocardiography. RESULTS: The overall treatment effectiveness rate was 85.19%. The serum soluble ST2 and BNP levels in the ineffective group were significantly higher compared to the effective group (P<0.05). Additionally, LVEF was significantly lower, while the left ventricular end-systolic dimension (LVESD) was significantly greater in the ineffective group than in the effective group. Both serum sST2 and BNP were identified as independent risk factors for ineffective treatment. A combined predictive model incorporating soluble ST2 and BNP achieved an AUC of 0.929, demonstrating excellent predictive performance. CONCLUSION: Baseline serum sST2 and BNP levels are independent predictors of treatment response in HF patients. Their combined application enhances predictive performance and may assist clinicians in tailoring treatment strategies to improve patient survival quality and prognosis.
No takes yet. Share an insight, caveat, or question.
Xiaoming Zhang (2025) conducted a case-control in Heart failure (n=162). Elevated baseline serum sST2 and BNP levels vs. Lower baseline levels was evaluated on Treatment inefficacy (improvement of <1 NYHA class or worsening) (OR 11.663, 95% CI 3.239-41.997, p=<0.001). Elevated baseline serum sST2 (OR 11.663) and BNP (OR 11.862) levels independently predicted ineffective treatment response in heart failure patients, with a combined model achieving an AUC of 0.929.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: